Evercore ISI Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price

Baxter International (NYSE:BAX) had its price target lowered by equities research analysts at Evercore ISI from $31.00 to $24.00 in a research note issued on Thursday,MarketScreener reports. Evercore ISI’s target price suggests a potential upside of 29.98% from the company’s current price.

Other analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Baxter International in a report on Wednesday, October 8th. UBS Group dropped their target price on shares of Baxter International from $24.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday. Jefferies Financial Group dropped their target price on shares of Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday. Cowen reiterated a “hold” rating on shares of Baxter International in a report on Thursday. Finally, Argus reiterated a “hold” rating on shares of Baxter International in a report on Friday. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.70.

Baxter International Stock Down 3.6%

Baxter International stock opened at $18.47 on Thursday. The stock has a market cap of $9.48 billion, a price-to-earnings ratio of -61.55, a PEG ratio of 0.73 and a beta of 0.58. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30. The company’s 50-day moving average price is $23.14 and its two-hundred day moving average price is $26.85. Baxter International has a 52 week low of $18.42 and a 52 week high of $37.74.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, beating the consensus estimate of $0.60 by $0.09. The firm had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.88 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. Baxter International’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.80 EPS. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. On average, analysts expect that Baxter International will post 2.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox grew its position in Baxter International by 1.3% during the second quarter. Dodge & Cox now owns 52,121,620 shares of the medical instruments supplier’s stock valued at $1,578,243,000 after purchasing an additional 662,695 shares in the last quarter. Geode Capital Management LLC grew its position in Baxter International by 2.6% during the second quarter. Geode Capital Management LLC now owns 12,882,960 shares of the medical instruments supplier’s stock valued at $388,416,000 after purchasing an additional 326,652 shares in the last quarter. Ameriprise Financial Inc. grew its position in Baxter International by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after purchasing an additional 97,687 shares in the last quarter. Sound Shore Management Inc. CT grew its position in Baxter International by 13.7% during the first quarter. Sound Shore Management Inc. CT now owns 2,825,902 shares of the medical instruments supplier’s stock valued at $96,731,000 after purchasing an additional 341,321 shares in the last quarter. Finally, Cooke & Bieler LP grew its position in Baxter International by 25.7% during the third quarter. Cooke & Bieler LP now owns 2,200,860 shares of the medical instruments supplier’s stock valued at $50,114,000 after purchasing an additional 450,350 shares in the last quarter. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.